Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-221 in advanced solid tumors
NCT02365662Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of losatuxizumab vedotin in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 2 more, sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events at 4 years, Maximum Plasma Concentration at 2 years and 3 more. Started Jan 2015; status: terminated.
02
Drugs
losatuxizumab vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal carcinoma (CRC)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02365662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365662.